HM6A.F Hypera S.A.

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
3.60 EUR
Close of Nov 12, 2026
3.16 4.88
Market cap
EUR 2.53B
P/E
8.0x
P/B
1.06x
ROE
12.3%
Dividend yield
5.02%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HM6A.F undervalued?

Graham number
Price3.60
Graham value5.88
Discount38.7%

HM6A.F trades 38.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hypera S.A. fundamental analysis

No fundamental analysis for Hypera S.A. yet.

Hypera S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hypera S.A.

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under A…

Full company profile